| $385M | ||
| $350M | ||
| $215M | ||
| $100M | ||
| $95M | ||
| $91M |
Buys | $60,000,008 | 1 | 25 |
Sells | $2,223,137 | 3 | 75 |
| BAKER BROS. ADVISORS LP | 1 | $60M | 0 | $0 | $60M | |
| BORGESON JOHN A. | See Remarks | 0 | $0 | 3 | $2.22M | $-2.22M |
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
Over the last 12 months, insiders at Kodiak Sciences Inc. have bought $60M and sold $2.22M worth of Kodiak Sciences Inc. stock.
On average, over the past 5 years, insiders at Kodiak Sciences Inc. have bought $94.1M and sold $4.03M worth of stock each year.
Highest buying activity among insiders over the last 12 months: BAKER BROS. ADVISORS LP () — $60M.
The last purchase of 2,608,696 shares for transaction amount of $60M was made by BAKER BROS. ADVISORS LP () on 2025‑12‑18.
| 2026-06-04 | Sale | BORGESON JOHN A. | Chief Financial Officer | 30,000 0.0566% | $34.10 | $1.02M | -6.51% | |
| 2026-04-02 | Sale | BORGESON JOHN A. | Chief Financial Officer | 30,000 0.0528% | $39.92 | $1.2M | +1.90% | |
| 2025-12-18 | BAKER BROS. ADVISORS LP | 2.61M 4.2971% | $23.00 | $60M | +6.29% | |||
| 2025-06-17 | Sale | BORGESON JOHN A. | See Remarks | 723 0.0014% | $3.65 | $2,640 | +532.11% | |
| 2024-06-17 | Sale | BORGESON JOHN A. | See Remarks | 2,874 0.0053% | $2.75 | $7,904 | +34.57% | |
| 2024-06-12 | Sale | BORGESON JOHN A. | See Remarks | 1,558 0.0031% | $2.92 | $4,549 | +28.67% | |
| 2023-06-16 | Sale | BORGESON JOHN A. | See Remarks | 2,749 0.0054% | $9.23 | $25,373 | -64.78% | |
| 2023-06-16 | Sale | EHRLICH JASON | See Remarks | 2,258 0.0044% | $9.23 | $20,841 | -64.78% | |
| 2023-06-14 | Sale | BORGESON JOHN A. | See Remarks | 1,448 0.0029% | $9.42 | $13,640 | -64.84% | |
| 2023-06-14 | Sale | EHRLICH JASON | See Remarks | 1,132 0.0023% | $9.42 | $10,663 | -64.84% | |
| 2022-06-15 | Sale | BORGESON JOHN A. | See Remarks | 2,798 0.0053% | $7.02 | $19,642 | +3.65% | |
| 2022-06-15 | Sale | EHRLICH JASON | See Remarks | 2,282 0.0043% | $7.02 | $16,020 | +3.65% | |
| 2022-06-02 | BAKER FELIX | 13,155 0.0255% | $7.93 | $104,363 | -6.75% | |||
| 2022-05-25 | BAKER FELIX | 116 0.0002% | $6.75 | $784 | +10.48% | |||
| 2022-05-16 | BAKER FELIX | 8,118 0.0163% | $5.99 | $48,599 | +29.47% | |||
| 2022-02-25 | Sale | PERLROTH VICTOR | Chairman and CEO | 340,000 0.6641% | $8.99 | $3.06M | -12.81% | |
| 2022-02-24 | Sale | PERLROTH VICTOR | Chairman and CEO | 1M 1.9233% | $9.20 | $9.2M | -16.03% | |
| 2022-02-17 | BAKER BROS. ADVISORS LP | 300,000 0.5801% | $54.56 | $16.37M | -28.56% | |||
| 2022-02-16 | BAKER BROS. ADVISORS LP | 95,165 0.1782% | $54.12 | $5.15M | -30.14% | |||
| 2022-02-15 | BAKER BROS. ADVISORS LP | 5,800 0.0107% | $54.16 | $314,099 | -31.11% |
| BAKER BROS. ADVISORS LP | 18358772 34.6849% | $570.04M | 42 | 0 | +11.65% | |
| BORGESON JOHN A. | Chief Financial Officer | 211930 0.4004% | $6.58M | 0 | 11 | |
| BAKER FELIX | 15617369 29.5056% | $484.92M | 3 | 0 | +11.07% | |
| PERLROTH VICTOR | Chairman and CEO | 2168038 4.096% | $67.32M | 0 | 2 | |
| Liang Hong | SVP, Discovery Medicine | 130166 0.2459% | $4.04M | 0 | 3 | |
| EHRLICH JASON | See Remarks | 61924 0.117% | $1.92M | 0 | 32 | |
| PROFUSEK ROBERT | director | 10000 0.0189% | $310,500.00 | 1 | 0 | <0.0001% |
| Levy Richard S | director | 1000 0.0019% | $31,050.00 | 1 | 0 | +41% |
$8,217,280 | 112 | 46.33% | $1.56B | |
$21,345,882 | 83 | 94.45% | $1.77B | |
$54,660,406 | 66 | 22.24% | $1.81B | |
$47,419,530 | 58 | 17.20% | $1.66B | |
$108,353,116 | 49 | 15.41% | $1.77B | |
Kodiak Sciences Inc. (KOD) | $613,304,943 | 46 | 11.85% | $1.64B |
$530,111,731 | 35 | 8.69% | $1.66B | |
$151,136,640 | 31 | -1.41% | $1.72B | |
$9,416,780 | 27 | -3.01% | $1.78B | |
$26,032,619 | 26 | 9.52% | $1.67B | |
$169,680,836 | 23 | 31.33% | $1.51B | |
$154,554,190 | 14 | 29.60% | $1.68B | |
$3,101,788 | 13 | 41.97% | $1.54B | |
$278,247,340 | 12 | 58.08% | $1.46B | |
$69,805,526 | 11 | 41.69% | $1.57B | |
$93,268,646 | 8 | -37.22% | $1.58B | |
$46,235,722 | 6 | -31.77% | $1.52B | |
$103,599,972 | 2 | -36.81% | $1.48B | |
$504,640 | 1 | 16.84% | $1.52B |
| Increased Positions | 100 | +81.97% | 17M | +39.37% |
| Decreased Positions | 53 | -43.44% | 4M | -10.02% |
| New Positions | 51 | New | 7M | New |
| Sold Out Positions | 13 | Sold Out | 1M | Sold Out |
| Total Postitions | 169 | +38.52% | 57M | +29.35% |
| Baker Bros. Advisors Lp | $450,419.00 | 28.85% | 17.31M | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $76,821.00 | 4.92% | 2.95M | -627,061 | -17.52% | 2025-09-30 |
| Point72 Asset Management, L.P. | $73,822.00 | 4.73% | 2.84M | +2M | +526.72% | 2025-09-30 |
| Vanguard Group Inc | $50,747.00 | 3.25% | 1.95M | +127,991 | +7.02% | 2025-09-30 |
| Adage Capital Partners Gp, L.L.C. | $34,737.00 | 2.23% | 1.33M | -720,707 | -35.06% | 2025-09-30 |
| Iconiq Capital, Llc | $32,956.00 | 2.11% | 1.27M | 0 | 0% | 2025-09-30 |
| Tcg Crossover Management, Llc | $29,807.00 | 1.91% | 1.15M | 0 | 0% | 2025-09-30 |
| Silverarc Capital Management, Llc | $26,020.00 | 1.67% | 1M | +598,460 | +149.04% | 2025-09-30 |
| Acadian Asset Management Llc | $25,237.00 | 1.62% | 969,906 | -999,970 | -50.76% | 2025-09-30 |
| State Street Corp | $21,660.00 | 1.39% | 832,443 | -4,778 | -0.57% | 2025-09-30 |